CA2578709A1 - Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents - Google Patents

Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents Download PDF

Info

Publication number
CA2578709A1
CA2578709A1 CA002578709A CA2578709A CA2578709A1 CA 2578709 A1 CA2578709 A1 CA 2578709A1 CA 002578709 A CA002578709 A CA 002578709A CA 2578709 A CA2578709 A CA 2578709A CA 2578709 A1 CA2578709 A1 CA 2578709A1
Authority
CA
Canada
Prior art keywords
composition
formulated
weight
minute
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002578709A
Other languages
French (fr)
Other versions
CA2578709C (en
Inventor
Philip J. Bromley
Lee N. Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virun Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2578709A1 publication Critical patent/CA2578709A1/en
Application granted granted Critical
Publication of CA2578709C publication Critical patent/CA2578709C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Compositions and methods for mucosal delivery of agents are provided. The compositions are intended for administration to mucosal surface, such as oral and nasal mucosa. The compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.

Claims (165)

What is claimed is:
1. A composition, comprising:
a mucoadhesive protein; and an agent for delivery, wherein:
the composition is formulated for mucosal delivery;
the composition contains a delivery vehicle associated with the agent;
and the mucoadhesive protein is associated with the delivery vehicle.
2. The composition of claim 1, wherein the composition is formulated as an emulsion for mucosal delivery.
3. The composition of claim 1 or 2, wherein the composition is formulated to contact a mucosal surface for an amount of time, whereby quantitative delivery of the agent is effected.
4. The composition of any of claims 1-3, wherein the composition is formulated to adhere or penetrate into the mucosal surface for an amount of time, whereby quantitative delivery of the agent is effected.
5. The composition of any of claims 1-4, wherein the composition formulated to adhere to the mucosal surface.
6. The composition of any of claims 1-4, wherein the composition is formulated to penetrate into the mucosal surface.
7. The composition of any of claims 1-3, wherein the composition is formulated to adhere to and penetrate into a mucosal surface.
8. The composition of any of claims 1-3, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 24 hours.
9. The composition of any of claims 1-3 and 8, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 18 hours.
10. The composition of any of claims 1-3, 8 and 9, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 12 hours.
11. The composition of any of claims 1-3 and 8-10, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 6 hours.
12. The composition of any of claims 1-3 and 8-11, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 180 minutes.
13. The composition of any of claims 1-3 and 8-12, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 150 minutes.
14. The composition of any of claims 1-3 and 8-13, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 120 minutes.
15. The composition of any of claims 1-3 and 8-14, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 90 minutes.
16. The composition of any of claims 1-3 and 8-15, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 60 minutes.
17. The composition of any of claims 1-3 and 8-16, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 50 minutes.
18. The composition of any of claims 1-3 and 8-17, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 30 minutes.
19. The composition of any of claims 1-3 and 8-18, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 20 minutes.
20. The composition of any of claims 1-3 and 8-19, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 10 minutes.
21. The composition of any of claims 1-3 and 8-20, wherein the composition is formulated to contact the mucosal surface from about 1 minute up to about 5 minutes.
22. The composition of any of claims 1-4, wherein the composition is formulated to adhere to or penetrate into the mucosal surface from about 1 minute up to about 24 hours.
23. The composition of any of claims 1-4 and 22, wherein the composition is formulated to adhere to or penetrate into the mucosal surface from about 1 minute up to about 12 hours.
24. The composition of any of claims 1-4, 22 and 23, wherein the composition is formulated to adhere to or penetrate into the mucosal surface from about 1 minute up to about 6 hours.
25. The composition of any of claims 1-3 and 22-24, wherein the composition is formulated to adhere to or penetrate into the mucosal surface from about 1 minute up to about 180 minutes.
26. The composition of any of claims 1-3 and 22-25, wherein the composition is formulated to adhere to or penetrate into the mucosal surface from about 1 minute up to about 30 minutes.
27. The composition of any of claims 1-3 and 22-26, wherein the composition is formulated to adhere to or penetrate into the mucosal surface from about 1 minute up to about 5 minutes.
28. The composition of any of claims 1-3 and 7, wherein the composition is formulated to adhere to and penetrate into the mucosal surface from about 1 minute up to about 24 hours.
29. The composition of any of claims 1-3, 7 and 28, wherein the composition is formulated to adhere to and penetrate into the mucosal surface from about 1 minute up to about 12 hours.
30. The composition of any of claims 1-3, 7 and 28-29, wherein the composition is formulated to adhere to and penetrate into the mucosal surface from about 1 minute up to about 6 hours.
31. The composition of any of claims 1-3, 7 and 28-30, wherein the composition is formulated to adhere to and penetrate into the mucosal surface from about 1 minute up to about 180 minutes.
32. The composition of any of claims 1-3, 7 and 28-31, wherein the composition is formulated to adhere to and penetrate into the mucosal surface from about 1 minute up to about 30 minutes.
33. The composition of any of claims 1-3, 7 and 28-32, wherein the composition adheres and penetrates into to a mucosal surface from about 1 minute up to about 5 minutes.
34. The composition of any of claims 1-3 and 5, wherein the composition is formulated to adhere to the mucosal surface from about 1 minute up to about 24 hours.
35. The composition of any of claims 1-3, 5 and 34, wherein the composition is formulated to adhere to the mucosal surface from about 1 minute up to about 12 hours.
36. The composition of any of claims 1-3, 5 and 34-35, wherein the composition is formulated to adhere to the mucosal surface from about 1 minute up to about 6 hours.
37. The composition of any of claims 1-3, 5 and 34-36, wherein the composition is formulated to adhere to the mucosal surface from about 1 minute up to about 30 minutes.
38. The composition of any of claims 1-3, 5 and 34-37, wherein the composition is formulated to adhere to the mucosal surface from about 1 minute up to about 5 minutes.
39. The composition of any of claims 1-3 and 6, wherein the composition is formulated to penetrate into the mucosal surface from about 1 minute up to about 24 hours.
40. The composition of any of claims 1-3, 6 and 39, wherein the composition is formulated to penetrate into the mucosal surface from about 1 minute up to about 12 hours.
41. The composition of any of claims 1-3, 6 and 39-40, wherein the composition is formulated to penetrate into the mucosal surface from about 1 minute up to about 180 minutes.
42. The composition of any of claims 1-3, 6 and 39-41, wherein the composition is formulated to penetrate into the mucosal surface from about 1 minute up to about 30 minutes.
43. The composition of any of claims 1-3, 6 and 39-42, wherein the composition is formulated to penetrate into the mucosal surface from about 1 minute up to about 5 minutes.
44. The composition of any of claims 1-43, wherein the emulsion is an oil in water or a water in oil emulsion.
45. The composition of any of claims 1-44, wherein the delivery vehicle is selected from a micelle, inverse micelle, liposome, cubosome and a mixture thereof.
46. The composition of any of claims 1-45, wherein the mucoadhesive protein is associated with the delivery vehicle via a chemical or physical bond.
47. The composition of any of claims 1-46, wherein the agent is dissolved in the oil phase.
48. The composition of any of claims 1-47, wherein the agent is dissolved in the water phase.
49. The composition of any of claims 1-48, wherein the mucoadhesive protein is selected from a family of mucin proteins and transferrins.
50. The composition of any of claims 1-49, wherein the mucoadhesive protein is selected from bovine lactoferrin, human lactoferrin, lactoferrin binding proteins, recombinant human lactoferrin, lactoferricin, lactoferricin b, transferrin binding proteins, bovine transferrin, ovotransferrin, neutrophil granules, apo-lactoferrin, immunoglobulin, albumin and lanthanide-lactoferrin.
51. The composition of any of claims 1-50, wherein the mucoadhesive protein is selected from bovine lactoferrin, human lactoferrin, lactoferrin binding proteins, recombinant human lactoferrin, lactoferricin, lactoferricin b, transferrin binding proteins, bovine transferrin, ovotransferrin, neutrophil granules, apo-lactoferrin and lanthanide-lactoferrin.
52. The composition of any of claims 1-51, wherein the mucoadhesive protein is selected from bovine lactoferrin, human lactoferrin, albumin and immunoglobulin.
53. The composition of any of claims 1-52, wherein the mucoadhesive protein is lactoferrin.
54. The composition of any of claims 1-53, wherein the mucoadhesive protein is present in an amount sufficient to effect quantitative delivery of the agent.
55. The composition of any of claims 1-54, wherein the mucoadhesive protein is present at a concentration of about 0.1 weight % up to about 50 weight % of the total weight of the composition.
56. The composition of any of claims 1-55, wherein the mucoadhesive protein is present at a concentration of about 0.1 weight % up to about 30 weight % of the total weight of the composition.
57. The composition of any of claims 1-56, the mucoadhesive protein is present at a concentration of about 0.1 weight % up to about 20 weight % of the total weight of the composition.
58. The composition of any of claims 1-57, the mucoadhesive protein is present at a concentration of about 0.1 weight % up to about 15 weight % of the total weight of the composition.
59. The composition of any of claims 1-58, wherein the mucoadhesive protein is present at a concentration of about 0.1 weight % up to about 12 weight % of the total weight of the composition.
60. The composition of any of claims 1-59, wherein the mucoadhesive protein is present at a concentration of about 0.1 weight % up to about 10 weight % of the total weight of the composition.
61. The composition of any of claims 1-60, wherein the mucoadhesive protein is present at a concentration of about 0.1 weight % up to about 8 weight % of the total weight of the composition.
62. The composition of any of claims 1-61, wherein the mucoadhesive protein is present at a concentration of about 0.1 weight % up to about 5 weight % of the total weight of the composition.
63. The composition of any of claims 1-62, wherein the mucoadhesive protein is present at a concentration of about 15 weight % of the total weight of the composition.
64. The composition of any of claims 1-63, wherein the mucoadhesive protein is present at a concentration of about 12 weight % of the total weight of the composition.
65. The composition of any of claims 1-64, wherein the mucoadhesive protein is present at a concentration of about 10 weight % of the total weight of the composition.
66. The composition of any of claims 1-65, wherein the mucoadhesive protein is present at a concentration of about 8 weight % of the total weight of the composition.
67. The composition of any of claims 1-66, wherein the mucoadhesive protein is present at a concentration of about 6 weight % of the total weight of the composition.
68. The composition of any of claims 1-67, wherein the mucoadhesive protein is present at a concentration of about 4 weight % of the total weight of the composition.
69. The composition of any of claims 1-68, wherein the mucoadhesive protein is present at a concentration of about 4 weight % of the total weight of the composition.
70. The composition of any of claims 1-69, wherein the mucoadhesive protein is present at a concentration of about 2 weight % of the total weight of the composition.
71. The composition of any of claims 1-70, wherein the mucoadhesive protein is present at a concentration of about 1 weight % of the total weight of the composition.
72. The composition of any of claims 1-71, wherein the mucoadhesive protein is present at a concentration of about 0.8 weight % of the total weight of the composition.
73. The composition of any of claims 1-72, wherein the mucoadhesive protein is present at a concentration of about 0.6 weight % of the total weight of the composition.
74. The composition of any of claims 1-73, wherein the mucoadhesive protein is present at a concentration of about 0.4 weight % of the total weight of the composition.
75. The composition of any of claims 1-74, wherein the mucoadhesive protein is present at a concentration of about 0.1 weight % of the total weight of the composition.
76. The composition of any of claims 1-75, wherein the agent is for altering a body function or altering cosmetic appearance.
77. The composition of any of claims 1-76, wherein the agent is for a therapeutic agent.
78. The composition of any of claims 1-77, wherein the agent is a drug.
79. The composition of any of claims 1-78, wherein the agent is a polypeptide drug.
80. The composition of any one of claims 1-77, wherein the agent is selected from antidiabetic, anticonvulsants, analgesics, antiparkinsons, anti-inflammatories, calcium antagonists, anesthetics, antimicrobials, antimalarials, antiparasitics, antihypertensives, antihistamines, antipyretics, alpha-adrenergic agonists, alpha-blockers, biocides, bactericides, bronchial dilators, beta-adrenergic blocking drugs, contraceptives, cardiovascular drugs, calcium channel inhibitors, depressants, diagnostics, diuretics, electrolytes, enzymes, hypnotics, hormones, hypoglycemics, hyperglycemics, muscle contractants, muscle relaxants, neoplastics, glycoproteins, nucleoproteins, lipoproteins, non-denatured whey protein, ophthalmics, psychic energizers, sedatives, steroids, sympathomimetics, parasympathomimetics, tranquilizers, urinary tract drugs, vaccines, vaginal drugs, vitamins, minerals, nonsteroidal anti-inflammatory drugs, angiotensin converting enzymes, polynucleotides, polypeptides, polysaccharides, and nutritional supplements.
81. The composition of any one of claims 1-76, wherein the agent is selected from hormones and nutritional supplements.

82. The composition of any one of claims 1-80, wherein the agent is an anti-diabetic.
82. The composition of any one of claims 1-81, wherein the agent is insulin.
83. The composition of any one of claims 1-80, wherein the agent is a nutritional supplement.
84. The composition of any of claims 1-79, wherein the agent is CoQ 10.
85. The composition of any one of claims 1-79, wherein the agent is a hormone.
86. The composition of any of claims 1-79 and 85, wherein the hormone is testosterone.
87. The composition of any of claims 1-79, wherein the agent is IGF-1.
88. The composition of any one of claims 1-79, wherein the agent is a vitamin.
89. The composition of any one of claims 1-79, wherein the agent is a mineral.
90. The composition of claim 89, wherein the mineral is calcium.
91. The composition of any one of claims 1-89, comprising a second agent.
92. The composition of claim 91 , wherein the two agents are testosterone and vinpocetin.
93. The composition of claim 91, wherein the two agents are hexarelin and GHRP-6.
94. The composition of any of claims 44-93, wherein the oil phase comprises a biocompatible oil.
95. The composition of any of claims 44-94, wherein the oil is obtained from a vegetable or animal origin.
96. The composition of any of claims 44-94, wherein the oil is a synthetic or semisynthetic oil.
97. The composition of any of claims 44-94, wherein the oil phase further comprises a medium-chain monoglyceride, diglyceride or triglyceride.
98. The composition of any of claims 44-94, wherein the oil phase further comprises a medium-chain triglyceride.
zz99. The composition of any of claims 44-94, wherein the oil phase comprises oat oil and a medium chain triglyceride.
100. The composition of any of claims 44-99, wherein the oil is present at a concentration of about 5 weight % up to about 90 weight % of the total weight of the composition.
101. The composition of any of claims 44-100, wherein the oil is present at a concentration of about 5 weight % up to about 40 weight % of the total weight of the composition.
102. The composition of any of claims 1-101, further comprising a surface active agent.
103. The composition of any of claims 102, wherein the surface active agent is selected from sodium lauryl sulfate; sorbitan laurate, sorbitan palmitate, sorbitan stearate, polysorbates, benzalkonium chloride, mixed chain phospholipids, cationic lipids, oligolipids, phospholipids, carnitines, sphingosines, sphingomyelins, ceramides, glycolipids, lipoproteins, apoproteins, amphiphilic proteins, amphiphilic peptides, amphiphilic synthetic polymers, and combinations thereof.
104. The composition of claim 102 or 103, wherein the surface active agent is selected from polysorbate-80, lecithin and phosphatidylcholine.
105. The composition of any of claims 102-104, wherein the surface active agent is present at a concentration of about 1 weight % up to about 30 weight % of the total weight of the composition.
106. The composition of any of claims 1-105 further comprising a cosolvent.
107. The composition of claim 106, wherein the cosolvent is selected from is a polyhydric alcohol or combination of polyhydric alcohols.
108. The composition of claims 106 or 107, wherein the cosolvent is selected from ethylene glycol, dipropylene glycol, propylene glycol, polyethylene glycol, glycerin, butylene glycol, hexylene glycol, polyoxyethylene, polypropylene glycol, sorbitol, ethylene glycol, and a mixture thereof.
109. The composition of any of claims 106-108, wherein the cosolvent is propylene glycol.
110. The composition of claims 106 or 109, wherein the propylene glycol is present at a concentration of about 1 weight % up to about 30 weight % of the total weight of the total composition.
111. The composition of any of claims 1-110 further comprising one or more other additives selected from taste modifying agents, a buffering agent, a chelating agent, a colorant, an osmotic modifier, a preservative, a sterilizer, a solubilizer, a tonicifier, a trace element, and a viscomodulator.
112. The composition of claim 111, wherein the taste modifying agents are selected from flavoring agents, sweetening agents and taste masking agents.
113. The composition of claims 111 or 112, wherein the taste modifying agent is selected from vanilla, cream custard, banana, fudge, butterscotch, coconut and chocolate.
114. The composition of any of claims 1-113, formulated for oral administration.
115. The composition of any of claims 1-113, formulated for nasal administration.
116. The composition of any of claims 1-115 that has a viscosity of about 10 cps up to about 500,000 cps.
117. The composition of any of claims 1-116 that has a viscosity of about 10 cps up to about 500,000 cps.
118. The composition of any of claims 1-117 that has a viscosity of about 10 cps up to about 300,000 cps.
119. The composition of any of claims 1-118 that has a viscosity of about 10 cps up to about 200,000 cps.
120. The composition of any of claims 1-119 that has a viscosity of about 10 cps up to about 100,000 cps.
121. The composition of any of claims 1-120 that has a viscosity of about 10 cps up to about 75,000 cps.
122. The composition of any of claims 1-121 that has a viscosity of about 10 cps up to about 50,000 cps.
123. The composition of any of claims 1-122 that has a viscosity of about 10 cps up to about 25,000 cps.
124. The composition of any of claims 1-123 that has a viscosity of about 10 cps up to about 10,000 cps.
125. The composition of any of claims 1-124 that has a viscosity of about 10 cps up to about 5,000 cps.
126. The composition of any of claims 1-125 that has a viscosity of about 10 cps up to about 3,000 cps.
127. The composition of any of claims 1-126 that has a viscosity of about 10 cps up to about 1,000 cps.
128. The composition of any of claims 1-127 that has a viscosity of about 10 cps up to about 500 cps.
129. The composition of any of claims 1-128 that has a viscosity of about 10 cps up to about 100 cps.
130. The composition of any of claims 1-129 that has a viscosity of about 10 cps up to about 75 cps.
131. The composition of any of claims 1-130 that has a viscosity of about 10 cps up to about 50 cps.
132. The composition of any of claims 1-131 that has a viscosity of about 10 cps up to about 20 cps.
133. The composition of any of claims 1-132 that has a viscosity of about 10 cps.
134. A method for mucosal delivery of an agent, comprising:
contacting the composition of any of claims 1-133 with a mucosal surface of a subject, whereby the agent is delivered into the circulatory system of the subject.
135. The method of claim 134, wherein the agent is a drug.
136. The method of claims 134 or 135, wherein the composition is formulated to contact a mucosal lining for a period of time that is sufficient for a quantitative delivery of the agent.
137. The method of claims 134-136, wherein the composition is formulated to adhere to or penetrate into the mucosal lining for a period of time that is sufficient for a quantitative delivery of the agent.
138. The method of claims 134-136, wherein the composition is formulated to adhere to and penetrate into the mucosal lining for a period of time that is sufficient for a quantitative delivery of the agent.
139. The method of claims 134-136, wherein the composition adheres to a mucosal lining for a period of time that is sufficient for a quantitative delivery of the agent.
140. The method of claims 134-136, wherein the composition is formulated to penetrate into the mucosal lining for a period of time that is sufficient for a quantitative delivery of the agent.
141. A method for making a composition of any of claims 1-133, comprising:
dissolving components in the composition in an oil and water phase and mixing the two phases at a predetermined temperature and pressure, whereby the mucoadhesive protein is associated with the delivery vehicle.
142. The method of claim 141, wherein the dissolving and the mixing steps are carried out at a same temperature.
143. The method of claim 142, wherein the dissolving and the mixing steps are carried out at different temperatures.
144. The method of any of claims 141-143, wherein the temperature during the dissolving and mixing step is maintained at a level that prevents denaturation of the mucoadhesive protein.
145. The method of any of claims 141-144, wherein the temperature during the dissolving and mixing step is maintained between about 60° F
to about 150°F.
146. The method of any of claims 141-145, wherein the temperature during the dissolving and mixing step is maintained between about 60° F
to about 120°F.
147. The method of any of claims 141-146, wherein the temperature during the dissolving and mixing step is maintained at about 115° F.
148. The method of any of claims 141-147, wherein the pressure during the dissolving and mixing step is maintained at about 20-35 PSI.
149. The method of any of claims 141-148, wherein the pressure during the dissolving and mixing step is maintained at about 25 PSI.
150. The method of any of claims 141-149, wherein the mixing step is carried out at about 100 rpm up to about 60,000 rpm.
151. The method of any of claims 141-150, wherein the mixing step is carried out at about 100 rpm up to about 40,000 rpm.
152. The method of any of claims 141-151, wherein the mixing step is carried out at about 100 rpm up to about 30,000 rpm.
153. The method of any of claims 141-152, wherein the mixing step is carried out at about 100 rpm up to about 10,000 rpm.
154. The method of any of claims 141-153, wherein the mixing step is carried out at about 100 rpm up to about 5,000 rpm.
155. The method of any of claims 141-154, wherein the mixing step is carried out at about 100 rpm up to about 2,000 rpm.
156. The method of any of claims 141-155, wherein the mixing step is carried out at about 100 rpm up to about 800 rpm.
157. The method of any of claims 141-156, wherein the mixing step is carried out at about 100 rpm up to about 400 rpm.
158. The method of any of claims 141-157, wherein the dissolving step is carried out at about 100 rpm up to about 500 rpm.
159. The method of any of claims 141-158, wherein the dissolving step is carried out at about 100 rpm up to about 300 rpm.
160. The method of any of claims 141-159, wherein the dissolving step is carried out at about 250 rpm.
161. The method of any of claims 141-160, wherein the dissolving step is carried out at about 200 rpm.
162. The method of any of claims 141-161, wherein the dissolving step is carried out at about 100 rpm.
163. A method of treating diabetes comprising:
administering the composition of any of claim 1-82 and 94-134 to a subject in need thereof.
164. A use of the composition of any of claims 1-82 and 94-134 for treating diabetes.
165. An article of manufacture containing the composition of any of claims 1-134, a packaging material for the composition and a label that indicates that the composition is for altering body function or altering cosmetic appearance.
CA2578709A 2004-06-17 2005-06-16 Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents Active CA2578709C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58087704P 2004-06-17 2004-06-17
US60/580,877 2004-06-17
PCT/US2005/021424 WO2006009825A1 (en) 2004-06-17 2005-06-16 Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents

Publications (2)

Publication Number Publication Date
CA2578709A1 true CA2578709A1 (en) 2006-01-26
CA2578709C CA2578709C (en) 2010-06-15

Family

ID=34982455

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2578709A Active CA2578709C (en) 2004-06-17 2005-06-16 Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents

Country Status (6)

Country Link
US (3) US7906140B2 (en)
EP (1) EP1768647B1 (en)
CN (1) CN101005828B (en)
CA (1) CA2578709C (en)
HK (1) HK1101554A1 (en)
WO (1) WO2006009825A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015132660A1 (en) * 2014-03-04 2015-09-11 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for transmucosal delivery and methods for treating diabetes in a subject in need thereof

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043253A1 (en) * 2003-08-19 2005-02-24 Cook Bradley R. Use of wound healing compositions for prevention of infections and allergies
PL1718283T3 (en) 2004-01-22 2013-08-30 Univ Miami Topical co-enzyme q10 formulations and methods of use
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US7906140B2 (en) 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
US20060039869A1 (en) * 2004-08-17 2006-02-23 Daniel Wermeling Intranasal delivery of antipsychotic drugs
SI2486942T1 (en) 2004-11-24 2019-03-29 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US7956031B2 (en) 2005-05-31 2011-06-07 Naidu Lp Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy
US8367126B2 (en) 2005-09-27 2013-02-05 University Of Kentucky Research Foundation Berry preparations and extracts
US7964223B2 (en) * 2005-09-27 2011-06-21 University Of Kentucky Research Foundation Berry preparations and extracts
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2007111933A2 (en) * 2006-03-22 2007-10-04 Intranasal Therapeutics , Inc. Pharmaceutical compositions comprising a hypoglycemic agent and methods of using same
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
US9386770B2 (en) * 2006-06-13 2016-07-12 Phibro Animal Health Corp. Use of predissolved pristinamycin-type and polyether ionophore type antimicrobial agents in the production of ethanol
CA2661274A1 (en) * 2006-08-29 2008-03-06 University Of Kentucky Research Foundation Compositions and methods for oral cancer chemoprevention using berry preparations and extracts
WO2008036258A2 (en) * 2006-09-18 2008-03-27 Aqueous Pharma Limited Collyrium for dry eye
US20080146672A1 (en) * 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
AU2008228764B2 (en) 2007-03-22 2014-05-08 Berg Llc Topical formulations having enhanced bioavailability
MX2009011286A (en) 2007-04-19 2010-04-01 Mary Kay Inc Magnolia extract containing compositions.
US20090099062A1 (en) * 2007-05-31 2009-04-16 Ethan Lee Pyrvinium For The Treatment of Cancer
GB0712905D0 (en) * 2007-07-04 2007-08-15 Reckitt Benckiser Uk Ltd Hard surface treatment compositions with improved mold or fungi remediation properties
WO2009009737A1 (en) * 2007-07-12 2009-01-15 Neurosci, Inc. Sustained release formulation of active pharmaceuticals in a lipid based sustained release
US9272034B2 (en) * 2007-10-04 2016-03-01 The Regents Of The University Of California Treatment of conditions related to shock
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
CA2704957A1 (en) 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
ES2962777T3 (en) * 2007-11-15 2024-03-21 Amgen Inc Antioxidant-stabilized aqueous antibody formulation for parenteral administration
EP3498299A1 (en) 2007-11-16 2019-06-19 Aclaris Therapeutics, Inc. Compositions and methods for treating purpura
AT506216B1 (en) * 2008-02-13 2009-07-15 Peter Dr Hernuss COMPOSITION FOR RECORDING MUCOSES TISSUE
DK2548456T3 (en) 2008-03-20 2015-09-28 Virun Inc Emulsions including (comprising) a PEG derivative of tocopherol
BRPI0909185A2 (en) 2008-03-20 2015-08-25 Virun Inc Vitamin E derivative and its uses
WO2009126764A1 (en) 2008-04-11 2009-10-15 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
JP4666004B2 (en) 2008-05-23 2011-04-06 富士ゼロックス株式会社 Fixing apparatus and image forming apparatus
US8337931B2 (en) * 2008-06-23 2012-12-25 Virun, Inc. Compositions containing non-polar compounds
US8877242B2 (en) 2008-07-14 2014-11-04 Polypid Ltd. Sustained-release drug carrier composition
US20100041622A1 (en) * 2008-08-13 2010-02-18 Bromley Philip J Compositions containing aminoalkanes and aminoalkane derivatives
EP2344202B1 (en) * 2008-09-08 2020-03-11 Children's Medical Center Corporation Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids
CN102438594A (en) 2009-04-24 2012-05-02 伊休蒂卡有限公司 A novel formulation of indomethacin
ES2614813T3 (en) 2009-04-30 2017-06-02 Midwestern University New therapeutic treatments using centaquine
KR20180018833A (en) 2009-05-11 2018-02-21 베르그 엘엘씨 Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
IN2012DN00570A (en) 2009-07-14 2015-06-12 Polypid Ltd
AU2010305200B2 (en) * 2009-10-08 2014-10-02 Phlora Bio-Technology Investment Limited Composition comprising benzoic acid in combination with organic acid preservatives as active components and use thereof
WO2011050135A1 (en) * 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
IT1397132B1 (en) * 2009-12-01 2013-01-04 Alfa Wassermann Spa COMPOSITIONS INCLUDING NON-STEROID ANTI-INFLAMMATORS.
SG183508A1 (en) 2010-03-12 2012-10-30 Berg Pharma Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
EP2563164B1 (en) 2010-03-23 2016-06-29 Virun, Inc. Nanoemulsion including sucrose fatty acid ester
GB201009673D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
DE202010012096U1 (en) * 2010-09-02 2010-11-11 Lorentz, Eckart, Dr. med. nose drops
MX336776B (en) 2010-09-07 2016-02-02 Dsm Nutritional Products Ag Comestible emulsions.
CA2813467A1 (en) 2010-10-02 2012-04-05 The Regents Of The University Of California Minimizing intestinal dysfunction
JP4752973B2 (en) * 2010-10-12 2011-08-17 富士ゼロックス株式会社 Fixing apparatus and image forming apparatus
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
ES2762451T3 (en) 2011-04-04 2020-05-25 Berg Llc Treatment of tumors of the central nervous system with coenzyme Q10
US9238153B2 (en) 2011-04-21 2016-01-19 Sunny Biodiscovery, Inc. Transoral methods and compositions for wrinkle reduction and cosmetic lip and facial augmentation
PE20140628A1 (en) 2011-06-17 2014-05-30 Berg Llc INHALABLE PHARMACEUTICAL COMPOSITIONS
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
CA2838481A1 (en) * 2011-07-27 2013-01-31 Polypid Ltd. Matrix compositions for controlled release of peptide and polypeptide molecules
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
WO2013120025A1 (en) 2012-02-10 2013-08-15 Virun, Inc. Beverage compositions containing non-polar compounds
CN103566376A (en) * 2012-08-09 2014-02-12 武汉英纳氏药业有限公司 Formula and preparation method of preparation delivered through mucous membrane
EP2934512B1 (en) 2012-12-18 2021-11-24 Kotzker Consulting LLC Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
BR112015025424A2 (en) 2013-04-08 2017-07-18 Berg Llc cancer treatment using coenzyme q10 combination therapies
WO2014186623A2 (en) * 2013-05-17 2014-11-20 Biomed Valley Discoveries Methods and compositions for the treatment of a chagas disease
US20150013695A1 (en) 2013-07-10 2015-01-15 Ahkeo Ventures LLC Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
AU2014315186B2 (en) 2013-09-04 2020-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
US10774288B2 (en) * 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
CN106459137B (en) * 2014-05-01 2019-04-12 整体生物系统有限责任公司 For treating the film adhesion self-assembly system of eye disorders
EP2946788A1 (en) 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
DE102014009164A1 (en) * 2014-06-03 2015-12-03 Herbalist & Doc Gesundheitsgesellschaft Mbh Silicone oil containing nasal formulations
US20170112947A1 (en) * 2014-06-05 2017-04-27 The Trustees Of Columbia University In The City Of New York Composition for use in imaging
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US20160051495A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America Oral Transmucosal Compositions including C-SERMs for Low Testosterone Levels in Men
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
CN108348775B (en) 2015-09-15 2021-07-02 普瑞西斯生物学研究有限责任公司 Prodrugs of fenkafamine
CA2996414A1 (en) 2015-09-18 2017-03-23 Virun, Inc. Compositions for providing agents that degrade in water
CN106924715A (en) * 2015-12-31 2017-07-07 深圳翰宇药业股份有限公司 terlipressin liposome and preparation method thereof
CN105688208A (en) * 2016-03-04 2016-06-22 刘文霞 Compound particles for treating retinal vasculitis and preparation method thereof
US20210284688A1 (en) * 2016-07-15 2021-09-16 Board Of Regents, The University Of Texas System Mucus-penetrating peptides and screening assay
CN106496309A (en) * 2016-11-24 2017-03-15 北京开景基因技术有限公司 Microballoon antigen and preparation method thereof and the preparation method of anti-cotinine antibody
US20190307886A1 (en) * 2016-12-23 2019-10-10 University Of Copenhagen A co-amorphous form of a substance and a protein
BR112019017865A2 (en) * 2017-02-28 2020-05-12 Biolingus Ip Llc OIL-BASED FORMULATIONS FOR SUBLINGUAL AND MOUTH DISPENSATION
DE102017104277A1 (en) 2017-03-01 2018-09-06 Lts Lohmann Therapie-Systeme Ag Transmucosal administration system for idebenone
EP3595635A4 (en) * 2017-03-15 2021-01-20 Vivavax Inc. Biocompatible and biodegradable emulsions and compositions, and methods of use thereof
WO2018174938A1 (en) 2017-03-23 2018-09-27 Virun, Inc. Stable dry powders and emulsions containing probiotics and mucoadhesive protein
WO2019049145A1 (en) * 2017-09-11 2019-03-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for nasal administration of drugs to brain and for systemic effect
CA3073527A1 (en) * 2017-09-12 2019-03-21 Academic Pharmaceuticals, Inc. Metolazone emulsion formulation
WO2019075127A1 (en) * 2017-10-10 2019-04-18 Vertice Pharma, Llc Midodrine hydrochloride oral solution and uses thereof
MX2020007246A (en) 2017-10-13 2020-11-13 Univ New York State Res Found Comprehensive vaccine design for commensal disease progression.
JP2021501161A (en) 2017-10-27 2021-01-14 ザ チルドレンズ メディカル センター コーポレーション Short-chain ceramide-based lipids and their use
AU2018372136B2 (en) * 2017-11-21 2022-01-27 Solventum Intellectual Properties Company Oral plant-based-oil-in-water emulsions and methods of use
CN112367985A (en) * 2018-01-31 2021-02-12 明尼苏达大学董事会 Compositions and methods for treating pulmonary edema or pneumonia
AU2019252912A1 (en) 2018-04-12 2020-10-22 The Children's Medical Center Corporation Ceramide-like lipid-based delivery vehicles and uses thereof
EP3813942B1 (en) * 2018-05-03 2024-04-17 Midwestern University Composition comprising centhaquin or a salt thereof for use in treating an individual suffering acute kidney function decline
US10383819B1 (en) 2018-07-23 2019-08-20 Callitas Therapeutics, Inc. Method to effect biphasic bioavailability of oral euphoric psychogenic cannabinoids
CA3110997A1 (en) * 2018-09-07 2020-03-12 Aquestive Therapeutics, Inc. Oral film compositions and dosage forms having precise active dissolution profiles
CN111821292A (en) * 2020-06-15 2020-10-27 中南大学湘雅二医院 Application method of nafamostat mesylate in treatment of chlamydia genital tract infection
WO2021263127A1 (en) * 2020-06-26 2021-12-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College A hypertension animal model and methods of use
US11052041B1 (en) 2020-10-01 2021-07-06 King Abdulaziz University Nanotechnology-based nostril drops for relief of respiratory ailments
CN113567364A (en) * 2021-06-11 2021-10-29 广东粤港供水有限公司 Chloral detection method and production line for chloral detection
WO2023096615A2 (en) * 2021-11-25 2023-06-01 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A compressed solid oral dosage form comprising pinaverium and medazepam

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3580384D1 (en) 1984-04-09 1990-12-13 Toyo Boseki PREPARATION WITH DELAYED RELEASE FOR APPLICATION ON THE ORIGINAL SLIME.
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
JPH0794384B2 (en) 1986-09-01 1995-10-11 帝国製薬株式会社 Sustained-release oral formulation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5234957A (en) 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4900552A (en) * 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5298246A (en) 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1994018955A1 (en) 1993-02-22 1994-09-01 Alza Corporation Compositions for oral delivery of active agents
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US6071535A (en) 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
CA2229286C (en) * 1998-02-10 2005-07-26 Generex Pharmaceuticals Inc. Mixed micellar delivery system and method of preparation
US6258383B1 (en) 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
US6861066B2 (en) 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
BR0311530A (en) 2002-05-23 2005-05-10 Umd Inc Compounds and release method for transmucosal drug and for cryoprotection
EP1539208A2 (en) 2002-06-28 2005-06-15 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein-stabilized liposomal formulations of pharmaceutical agents
AU2004296851A1 (en) * 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
WO2005085287A1 (en) 2004-03-03 2005-09-15 En-N-Tech, Inc. Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions
US7906140B2 (en) * 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
DK2548456T3 (en) 2008-03-20 2015-09-28 Virun Inc Emulsions including (comprising) a PEG derivative of tocopherol
BRPI0909185A2 (en) * 2008-03-20 2015-08-25 Virun Inc Vitamin E derivative and its uses
US8337931B2 (en) * 2008-06-23 2012-12-25 Virun, Inc. Compositions containing non-polar compounds
US20100041622A1 (en) * 2008-08-13 2010-02-18 Bromley Philip J Compositions containing aminoalkanes and aminoalkane derivatives
EP2563164B1 (en) 2010-03-23 2016-06-29 Virun, Inc. Nanoemulsion including sucrose fatty acid ester
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015132660A1 (en) * 2014-03-04 2015-09-11 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for transmucosal delivery and methods for treating diabetes in a subject in need thereof
US10568936B2 (en) 2014-03-04 2020-02-25 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for transmucosal delivery and methods for treating diabetes in a subject in need thereof

Also Published As

Publication number Publication date
CA2578709C (en) 2010-06-15
EP1768647B1 (en) 2012-08-08
US20110117184A1 (en) 2011-05-19
US20050281772A1 (en) 2005-12-22
WO2006009825A1 (en) 2006-01-26
US20120308644A1 (en) 2012-12-06
EP1768647A1 (en) 2007-04-04
US7906140B2 (en) 2011-03-15
US8414914B2 (en) 2013-04-09
HK1101554A1 (en) 2007-10-18
CN101005828A (en) 2007-07-25
US8252323B2 (en) 2012-08-28
CN101005828B (en) 2012-01-11

Similar Documents

Publication Publication Date Title
CA2578709A1 (en) Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
KR100439323B1 (en) Method and composition for delivering zinc to the nasal membrane
AU2003231943B2 (en) Topical drug delivery using phosphatidylcholine
EP0706374B1 (en) Method for preparing liposomes
Lee Changing needs in drug delivery in the era of peptide and protein drugs
AU767373B2 (en) Gum pad for delivery of medication to mucosal tissues
Woodle et al. Prolonged systemic delivery of peptide drugs by long-circulating liposomes: illustration with vasopressin in the Brattleboro rat
US10213490B2 (en) Compositions for providing agents that degrade in water
CA2630578C (en) Orally absorbed pharmaceutical formulation and method of administration
WO1991004014A1 (en) Method for transporting compositions across the blood brain barrier
EP0460100A1 (en) Liposome gel composition and method
JPH06316530A (en) Local insulin-containing preparation
US5366958A (en) Localized delivery using fibronectin conjugates
AU4674601A (en) Pharmaceutical compositions for buccal and pulmonary application
WO2008120207A2 (en) Compositions for nasal delivery
AU2003238862A1 (en) Formulations for amylin agonist peptides
AU2018255294A1 (en) Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout
NZ580967A (en) Composition comprising a bile salt and an effervescent excipient component for transmucosal delivery of polypeptides
EP1265638A1 (en) Compositions for transdermal and transmucosal administration of therapeutic agents
EP0711148A1 (en) Biphasic multilamellar lipid vesicles
JPH0499729A (en) Calcitonins-containing emulsion for nasogastric administration
MXPA02004776A (en) Treatment of subnormal bone mineral density.
CA2100720C (en) Medicinal composition comprising tcf-ii
US20080051332A1 (en) Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
CA2782751C (en) Transdermal therapeutic system for the administration of peptides

Legal Events

Date Code Title Description
EEER Examination request